Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lava Therapeutics N.V. (LVTX)

Lava Therapeutics N.V. (LVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 45,771
  • Shares Outstanding, K 26,305
  • Annual Sales, $ 11,980 K
  • Annual Income, $ -25,110 K
  • EBIT $ -30 M
  • EBITDA $ -32 M
  • 60-Month Beta 0.50
  • Price/Sales 3.97
  • Price/Cash Flow N/A
  • Price/Book 3.61
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.86
  • Most Recent Earnings $-0.27 on 11/06/25
  • Next Earnings Date 03/27/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.14
  • Growth Rate Est. (year over year) +713,671.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4500 +20.00%
on 10/22/25
1.8250 -4.66%
on 11/18/25
+0.2500 (+16.78%)
since 10/20/25
3-Month
1.4000 +24.29%
on 09/19/25
1.8250 -4.66%
on 11/18/25
+0.2150 (+14.10%)
since 08/20/25
52-Week
0.8502 +104.66%
on 02/12/25
2.0000 -13.00%
on 12/03/24
+0.2200 (+14.47%)
since 11/20/24

Most Recent Stories

More News
XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.

EMERYVILLE, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA) today announced it has successfully completed its previously announced acquisition of...

XOMA : 26.92 (-1.28%)
XOMAP : 26.33 (+0.32%)
XOMAO : 25.33 (-0.28%)
LVTX : 1.7400 (-3.87%)
Shareholder Alert: The Ademi Firm investigates whether LAVA Therapeutics N.V. is obtaining a Fair Price for its Public Shareholders in the Amendment to the Purchase Agreement

MILWAUKEE , Oct. 20, 2025 /PRNewswire/ --The Ademi Firm is investigating Lava (Nasdaq: LVTX) for possible breaches of fiduciary duty and other violations of law in its transaction with XOMA Royalty....

LVTX : 1.7400 (-3.87%)
XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement

- Amendment includes finalized cash amount and updated CVR terms for tender offer - LAVA announces new date for extraordinary general meeting of shareholders EMERYVILLE, Calif. and UTRECHT, The...

XOMA : 26.92 (-1.28%)
XOMAP : 26.33 (+0.32%)
XOMAO : 25.33 (-0.28%)
LVTX : 1.7400 (-3.87%)
LAVA Therapeutics Extends Tender Offer Deadline

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest...

LVTX : 1.7400 (-3.87%)
XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.

EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Oct. 02, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ: XOMA) and LAVA Therapeutics N.V. (“LAVA”)...

XOMA : 26.92 (-1.28%)
XOMAP : 26.33 (+0.32%)
XOMAO : 25.33 (-0.28%)
LVTX : 1.7400 (-3.87%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SCS, LVTX, ENZB on Behalf of Shareholders

NEW YORK , Aug. 8, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

ENZB : 0.6989 (+1.66%)
SCS : 16.14 (+0.12%)
LVTX : 1.7400 (-3.87%)
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of LAVA Therapeutics N.V. (NASDAQ: LVTX)

NEW YORK , Aug. 7, 2025 /PRNewswire/ -- Class Action Attorney  Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions...

LVTX : 1.7400 (-3.87%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SCS, HNI, LVTX, HLVX on Behalf of Shareholders

NEW YORK , Aug. 4, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

HNI : 47.88 (+0.74%)
SCS : 16.14 (+0.12%)
HLVX : 2.09 (-0.48%)
LVTX : 1.7400 (-3.87%)
LVTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Lava Therapeutics N.V. Is Fair to Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of LAVA Therapeutics N.V. (NASDAQ: LVTX) to XOMA Royalty Corporation is fair to LAVA shareholders. Under the terms of the...

LVTX : 1.7400 (-3.87%)
XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right

EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ: XOMA) and LAVA Therapeutics N.V. (“LAVA”)...

XOMA : 26.92 (-1.28%)
XOMAP : 26.33 (+0.32%)
XOMAO : 25.33 (-0.28%)
LVTX : 1.7400 (-3.87%)

Business Summary

LAVA Therapeutics B.V. is a biotechnology company. It focuses on applying its expertise in bispecific gamma-delta T cell engagers to transform cancer therapy. LAVA Therapeutics B.V. is based in UTRECHT, The Netherlands.

See More

Key Turning Points

3rd Resistance Point 2.0333
2nd Resistance Point 1.9267
1st Resistance Point 1.8333
Last Price 1.7400
1st Support Level 1.6333
2nd Support Level 1.5267
3rd Support Level 1.4333

See More

52-Week High 2.0000
Last Price 1.7400
Fibonacci 61.8% 1.5608
Fibonacci 50% 1.4251
Fibonacci 38.2% 1.2894
52-Week Low 0.8502

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar